Efficacy, Safety, and Tolerability of Oral Eletriptan for Treatment of Acute Migraine
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years to 78 Years (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
History of at least one typical attack of migraine with or without aura every 6 weeks, as defined by the International Headache Society (IHS) criteria.
Capable of taking study medication as outpatients and recording its effects.
Pregnant or breast-feeding women
Migraine subjects who also suffered from concomitant frequent (non-migraine) headache, defined as more than six headaches per month on average
Migraine attacks that were thought to be atypical and had consistently failed to respond to medical therapy.